9937 ISTH Gene Therapy Leavitt Podcast Evaluation

3. What is your role in the care of individuals with hemophilia? Select all that apply *This question is required.

• Physician involved in direct patient care (management and monitoring of bleeding risk)
• Investigator in clinical trials of patients with hemophilia
• Perform assays/assessments in a specialized coagulation laboratory
• Physical, occupational, and/or mental health therapy
• Basic research related to hemophilia, but not related to patient care
• Patient education
• Other, please specify Please enter an 'other' value for this selection.

6. Please rate your ability BEFORE the activity *This question is required.

Space Cell	0 - Not Relevant	1 - Low	2	3	4	5 - High
KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 0 - Not Relevant	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 1 - Low	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 2	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 3	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 4	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 5 - High
ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 0 - Not Relevant	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 1 - Low	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 2	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 3	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 4	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 5 - High
KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 0 - Not Relevant	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 1 - Low	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 2	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 3	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 4	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 5 - High

7. Please rate your ability AFTER the activity *This question is required.

Space Cell	0 - Not Relevant	1 - Low	2	3	4	5 - High
KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 0 - Not Relevant	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 1 - Low	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 2	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 3	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 4	KNOWLEDGE of the expected reliability and durability of gene therapy for hemophilia based on ongoing clinical trials:: 5 - High
ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 0 - Not Relevant	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 1 - Low	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 2	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 3	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 4	ABILITY to provide education to patients and peers about the expected therapeutic benefits of gene therapy related to annual bleed rates, factor usage, and target joints:: 5 - High
KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 0 - Not Relevant	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 1 - Low	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 2	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 3	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 4	KNOWLEDGE of the eligibility criteria that are likely to guide access to gene therapy for hemophilia:: 5 - High

Do you intend to make changes or apply new knowledge to your practice as a result of this activity? *This question is required.

• Yes*
• I’m possibly considering changes*
• This activity affirms what I already do in practice
• No, I do not intend to make any changes

*If yes, or possibly considering changes, please check off what you intend to do differently or incorporate into your clinical practice as a result of this educational activity. Select all that apply *This question is required.

• Obtain additional information on the potential benefits associated with gene therapy for hemophilia
• Follow current preclinical and clinical studies utilizing the AAV virus for hemophilia gene therapy
• Discuss efficacy and durability-related differences between the AAV vector serotypes currently in use for gene therapy with peers and colleagues
• Include efficacy and durability concerns in discussions of hemophilia gene therapy with patients and caregivers
• Other, please specify Please enter an 'other' value for this selection.

Was the format of this educational activity appropriate for the content presented?  *This question is required.

• Yes
• No

Did this educational activity meet your learning needs? *This question is required.

• Yes
• No

9. Was this activity scientifically sound and free of commercial bias or influence? *This question is required.

• Yes
• No

10. The France Foundation would like to email you educational opportunities relevant to your practice to the address you provided. May we have your consent? *This question is required.

• Yes
• No